Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$34,386 | -$41,443 | -$35,907 | -$37,546 |
| Dep. & Amort. | $120 | $141 | $156 | $160 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $6,833 | $6,741 |
| Change in WC | -$1,935 | $9,963 | -$11,074 | -$26,703 |
| Other Non-Cash | $5,833 | $6,091 | $168 | -$1,660 |
| Operating Cash Flow | -$30,368 | -$25,248 | -$39,824 | -$59,008 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$24 | -$17 | -$11 | -$20 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | -$58,740 | -$38,989 | $0 | $0 |
| Inv. Sales/Matur. | $64,000 | $62,000 | $0 | $65,000 |
| Other Inv. Act. | $0 | $0 | -$43,648 | $0 |
| Investing Cash Flow | $5,236 | $22,994 | -$43,659 | $64,980 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $191,111 | $0 | $65,577 | $0 |
| Stock Issued | $2,659 | $72 | $0 | $0 |
| Stock Repurch. | $0 | $0 | -$885 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$2,164 | -$103 | $970 | $110 |
| Financing Cash Flow | $191,606 | -$31 | $65,662 | $110 |
| Forex Effect | $619 | $606 | $197 | -$525 |
| Net Chg. in Cash | $167,093 | -$1,679 | -$17,624 | $5,557 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $58,085 | $59,764 | $78,837 | $73,280 |
| End Cash | $225,178 | $58,085 | $61,213 | $78,837 |
| Free Cash Flow | -$30,392 | -$25,265 | -$39,835 | -$59,028 |